Rigel Pharmaceuticals Welcomes Michael P. Miller to Board of Directors

Rigel Pharmaceuticals Welcomes a New Visionary

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) continues to assert its influence in the biotechnology landscape with the recent announcement of Michael P. Miller's appointment to its Board of Directors. With over 40 years of experience in leadership roles within the biotech and pharmaceutical industries, Miller’s expertise promises to enhance Rigel's strategic vision and operational execution.

A Legacy of Commercial Excellence

Michael P. Miller is a seasoned executive whose career has spanned various significant roles in prominent companies. His journey began in commercially-focused positions, where he honed his skills in market strategy and execution. As stated by Raul Rodriguez, Rigel's president and CEO, "Mike has a strong track record of commercial excellence, and we're delighted to have him join our Board. His extensive expertise will provide valuable insights as we execute our transformational strategic plan."

Before joining Rigel, Michael served as the Executive Vice President of U.S. Commercial at Jazz Pharmaceuticals; a position he held from April 2014 until September 2020. During that tenure, he was crucial in shaping the commercial strategy that drove substantial growth for the company. His prior experience includes senior leadership roles at well-respected organizations such as Vivus and Genentech, where he was integral in leading innovative oncology franchises and various pharmaceutical operations.

Expanding Strategic Horizons

Miller’s appointment is particularly crucial as Rigel seeks to grow its portfolio of medicines and explore potential in-licensing opportunities. His wealth of knowledge in commercial execution and strategic insight is viewed as an asset for navigating these opportunities and challenges. Mr. Rodriguez emphasized the board’s confidence in Miller’s ability to provide crucial guidance in this vital growth phase, particularly regarding Rigel's mission to improve treatment outcomes for patients facing hematologic disorders and cancer.

Commitment to Patient Outcomes

In a statement reflecting his enthusiasm for this new role, Miller remarked, "Over the years, I have seen Rigel evolve into a profitable company with a strong commercial engine. This unique position within the biotechnology space allows for the funding of a promising development pipeline. I am thrilled to join Rigel as a Director and to contribute to the critical work focused on realizing opportunities for serving more patients with hematologic disorders and cancer."

This aligns seamlessly with Rigel's dedication to developing innovative therapies aimed at significantly improving patient lives. Founded in 1996 and based in South San Francisco, Rigel is committed to addressing hematologic disorders and advancing cancer treatments through its robust pipeline of therapeutic candidates.

Looking Ahead

The addition of Michael P. Miller to the Board of Directors is seen as a strategic move that will potentially broaden Rigel's market approach and reinforce its commitment to patients. As the biotech industry continues to evolve with technological advancements and shifting regulatory landscapes, the leadership team, strengthened by Miller’s vision, is poised to take on new challenges and seize opportunities in the ever-competitive biosciences field.

For detailed updates on Rigel Pharmaceuticals and their innovative therapeutic developments, visit www.rigel.com.